DiagnoCure to host Q3 2013 earnings conference call and webcast
27 August 2013 - 9:30PM
OTC Markets
DiagnoCure to host Q3 2013 earnings conference call and webcast
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure to host Q3 2013 earnings conference call and webcast
PR Newswire
QUEBEC CITY, Aug. 27, 2013
QUEBEC CITY, Aug. 27, 2013 /PRNewswire/ - DiagnoCure Inc.
(TSX: CUR)
(OTCQX: DGCRF) announced today that it will release its third
quarter
2013 results on September 4, 2013, at
4:00 p.m. (EDT). DiagnoCure's
management will host a conference call the same day, at
4:30 p.m.
(EDT). Interested participants may listen to the call by
dialing
1-888-390-0546 or 514-225-6995 and referencing code 78274536
approximately 15 minutes prior to the call. The Corporation will
also
provide a live webcast of the call. Interested participants may
access
the webcast on DiagnoCure's website at www.diagnocure.com, through
a link on the Investors page - Presentations. A replay of
the
webcast will be available on DiagnoCure's website for those unable
to
participate in the live webcast.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory.
PrevistageTM GCC is currently available for licensing.
The Corporation has granted a
worldwide exclusive license on PCA3 to Gen-Probe, now a
wholly-owned
subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for
the
development and commercialization of a prostate cancer test,
DiagnoCure's proprietary molecular biomarker. Hologic
Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the
United States. For
more information, please visit www.diagnocure.com.
Forward?looking statements
This release contains forward?looking statements that involve known
and
unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected. By their very
nature,
forward?looking statements are based on expectations and hypotheses
and
also involve risks and uncertainties, known and unknown, many of
which
are beyond DiagnoCure's control. As a result, investors are
cautioned
not to place undue reliance on these forward?looking statements.
The
forward-looking statements regarding the outcome of research
and
development projects, clinical studies and future revenues are
based on
management expectations. In addition, the reader is referred to
the
applicable general risks and uncertainties described in
DiagnoCure's
most recent Annual Information Form under the heading "Risk
Factors".
DiagnoCure undertakes no obligation to publicly update or revise
any
forward?looking statements contained herein unless required by
the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jul 2023 to Jul 2024